Stock Evaluator: Abbott Laboratories (ABT)

2,025 followers

Abbott Laboratories ABT

$107.12 1.42 1.34%
August 3, 2026 4:04:13 PM EST November 10, 2021 Volume: 7,408,459
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NYSE | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Commentary & Analysis


Financial Summary

Share Statistics ABT Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $182,901.5 $337.2 98%
Shares Out (Mil) 1,743.0 41.9 97%
Institutional Ownership 99.4% 77.8% 88%
Float (Mil) 1,719.7 34.7 95%
Beta 0.61 0.85 35%
Avg Daily Volume (000s) 11,077 278 97%
Price Change
(52-week)
(17.8%) 58.7% 32%
Growth ABT Industry
Median
Percentile
(All Stocks)
Sales (5yr) 5.1% 11.8% 37%
Net Income (5yr) 7.7% (5.8%) 51%
EPS (5yr) 8.2% 11.4% 43
Dividends (5yr) 9.4% 0.0% 92%
Cash Flow (5yr) (20.9%) (16.3%) 31%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 22 25 25
Current EPS $1.419 $5.517 $6.063
Month Ago EPS $1.421 $5.482 $6.058
# Rev Up 0 0 1
# Rev Down 1 1 0
Three Months Ago EPS $1.419 $5.483 $6.064
Year/Year Chg 167.7% 48.3% 80.6%
Financials ABT Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $46,585 $152 96%
Net Income (TTM) (Mil) $5,425 ($10) 97%
EPS (TTM) $3.102 ($0.500) 79%
Operating Cash Flow (TTM) (Mil) $9,905 ($2) 98%
Net Cash Flow (TTM) (Mil) ($1,847) $1 2%
Long-Term Debt (Q1) (Mil) $29,703 $22 97%
Enterprise Value (Q1) (Mil) $214,650 $304 99%
Valuation ABT Industry
Median
Percentile
(All Stocks)
P/B 3.58 2.80 70%
P/E 34.2 31.1 73%
Dividend Yield 2.4% 0.0% 79%
PEG (5yr hist) 4.1 1.9 84%
Ratios ABT Industry
Median
Percentile
(All Stocks)
Gross Margin 56.8% 59.1% 69%
Net Margin 11.6% (7.3%) 67%
ROA 5.6% (13.7%) 75%
ROE 10.7% (15.8%) 60%
Liabilities to Assets 52.6% 44.7% 45%
F-Score 5 4 51%

Abbott Laboratories did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors